Atıf İçin Kopyala
Van Cutsem E., Boni C., Tabernero J., Massuti B., Middleton G., Dane F., ...Daha Fazla
ANNALS OF ONCOLOGY, cilt.26, sa.1, ss.149-156, 2015 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
26
Sayı:
1
-
Basım Tarihi:
2015
-
Doi Numarası:
10.1093/annonc/mdu496
-
Dergi Adı:
ANNALS OF ONCOLOGY
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.149-156
-
Anahtar Kelimeler:
antineoplastic agents, combined, platinum compounds, stomach neoplasms, taxoids, GASTROESOPHAGEAL JUNCTION, 1ST-LINE THERAPY, CISPLATIN, TRIAL, ADENOCARCINOMA, COMBINATION, EPIRUBICIN, CHEMOTHERAPY, DOXORUBICIN, MITOMYCIN
-
Marmara Üniversitesi Adresli:
Evet
Özet
Docetaxel/cisplatin/infusional 5-fluorouracil (5-FU; DCF) is a standard chemotherapy regimen for patients with advanced gastric cancer (GC). This phase II study evaluated docetaxel/oxaliplatin (TE), docetaxel/oxaliplatin/5-FU (TEF), and docetaxel/oxaliplatin/capecitabine (TEX) in patients with advanced GC.